This Is MS Multiple Sclerosis Knowledge & Support Community

European regulators rejected Merck KGaA’s multiple sclerosis pill cladribine, the second setback this week for the German drugmaker seeking to compete with Novartis AG for a share of a new market.

The European Medicines Agency found the medicine’s benefits don’t outweigh the risks, Darmstadt, Germany-based Merck said in a statement today. Merck is weighing an appeal and still believes cladribine has the potential to generate $1 billion in revenue a year, said Elmar Schnee, head of the company’s drug unit, in a telephone interview. The stock dropped the most in seven months.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1629

Isn't mad that some countries say ok to what could be very dangerous drugs whilst others feel the risk is too high??

Well lets see what happens with the Russian MS patients and the Australian MS patients who take it. I hope it works well and that the cancer risk is minimal. ( I have a feeling though that the cancer risk is probably very high)